Advertisement
Organisation › Details
Orphazyme (Group)
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). *
Start | 2009-06-01 established | |
Today | Orphazyme A/S (Nasdaq Copenhagen: ORPHA.CO) | |
Predecessor | Orphazyme ApS | |
Industry | enzyme replacement therapeutic | |
Industry 2 | DRUGS, ORPHAN | |
Region | København (Copenhagen) | |
Country | Denmark | |
Street | 3 Ole Maaløes Vej | |
City | 2200 Copenhagen N | |
Tel | +45-39-178272 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Centogene AG. (5/9/18). "Press Release: Centogene Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease". Rostock. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Orphazyme (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top